Experiment 3- Striatal LID markers expression after
administration of doxycycline
In this experiment, the immunoreactivity of FOS-B (a canonical protein
associated with LID), proteins typical of neuroinflammation such as
COX-2, GFAP, OX-42, MMPs, and the presence of ROS were evaluated. The
experimental groups comprised parkinsonian rats with already established
LID that were receiving acute doxycycline treatment and parkinsonian
rats receiving doxycycline treatment since day one as well as the
respective controls. An individual experimental group assembly was
prepared for each analysis described below.
Experiment 3.1. Striatal LID markers expression in rats
acutely treated with doxycycline once dyskinesia was present
(i) Immunohistochemical reaction for COX-2, GFAP, OX-42 in the
experimental groups: 6-OHDA+vehicle+L-DOPA, (n=7);
6-OHDA+doxycycline+L-DOPA (n=8) and the respective controls
[no-lesion+vehicle+vehicle; (n=6), 6-OHDA+vehicle+vehicle (n=5),
6-OHDA+doxycycline+vehicle (n=5)].
(ii) MMP-3 immunoblotting, MMP-2 and MMP-9 gel zymography in the
striatum of the experimental groups: 6-OHDA+vehicle+L-DOPA (n=7),
6-OHDA+doxycycline+L-DOPA (n=6), and the respective controls
[no-lesion+vehicle+vehicle (n=6), 6-OHDA+vehicle+vehicle, (n=6),
6-OHDA+DOX+vehicle (n=6)].
(iii) MMP-2/-9 in situ gelatinolytic zymography and ROS
histochemistry analysis in the brain sections of the experimental
groups: 6-OHDA+vehicle+L-DOPA (n=7), 6-OHDA+doxycycline+L-DOPA (n=7),
and the respective controls [no-lesion+vehicle+vehicle (n=6),
6-OHDA+vehicle+vehicle (n=6), 6-OHDA+doxycycline+vehicle (n=6)].